Arkolith/Insider Trading/INBX/Form 4

Lappe Mark

Chief Executive Officer, DirectorInhibrx Biosciences, Inc. (INBX) · full profile →Form 4 · filed Sep 10, 2024
Net Buying
Open-Market Buys
$671K
Open-Market Sells
$0
Net Open-Market Flow
$671K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 10, 2024Buy(P)9K$15.19$129K666K
Sep 9, 2024Buy(P)10K$15.21$144K657K
Sep 6, 2024Buy(P)26K$15.29$398K648K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002007919-24-000045) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML